Drug search by name

Xultophy 100/3.6 and Thyroid carcinoma

Result of checking the interaction of drug Xultophy 100/3.6 and disease Thyroid carcinoma for safety when used together.

Check result:

Xultophy 100/3.6 <> Thyroid carcinoma

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

GLP-1 receptor agonist antidiabetic drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Carcinogenicity studies in rodents and limited postmarketing data suggest that GLP-1 inhibitors may cause a dose-related and treatment duration-related increase in risk of thyroid C-cell tumors, although a causal relationship has not been established.

Xultophy 100/3.6

Generic Name: insulin degludec / liraglutide

Brand Name: Xultophy

Synonyms: Xultophy

What is Xultophy 100/3.6?